“Like many in my generation, I grew up with many of the standard stereotypes about cannabis: good people stay away from it, cannabis will only lead to serious antisocial behavior, there is nothing beneficial that could come from it. Many of the messages seemed to be directly from the 1936 propaganda film, Reefer Madness. The possibility of any sort of medicinal value stemming from cannabis never crossed my mind.”
“Following graduate school, I began my career working closely with healthcare organizations as a strategy consultant and market researcher. The complexity of the healthcare sector along with clinical aspects of how medicine works, and the financial/psychological drivers impact how decisions are made, was fascinating. However, the main driver was the belief that if I did my job well in helping our clients make better decisions, ultimately, it would translate into better patient outcomes.
In the many years I have been involved with healthcare, I heard stories of cannabis used for medicinal purposes. However, I found it hard to believe that a single plant could help with ailments as diverse as pain, anxiety, and sleep. I didn’t understand the underlying biological mechanism and failed to see the potential of this plant. It wasn’t until a few years ago, when a friend of mine informed me she was joining investment community focused exclusively on cannabis, that I started looking more closely into it. In reviewing the data, two things became clear: cannabis is medicine and we are witnessing the birth of a new industry.
Csequence is designed to address the uniqueness of this industry as it continues to evolve. It is an exhilarating time from the perspective of patients, investors and manufacturers, and Csequence is excited to be a part of it.”
-Sugata Biswas, Founder